BidaskClub lowered shares of Strongbridge Biopharma (NASDAQ:SBBP) from a buy rating to a hold rating in a research report released on Friday.
SBBP has been the topic of a number of other research reports. Cantor Fitzgerald set a $14.00 target price on Strongbridge Biopharma and gave the company a buy rating in a report on Wednesday, January 17th. HC Wainwright reissued a buy rating and issued a $18.00 target price on shares of Strongbridge Biopharma in a report on Thursday, January 18th. Finally, Zacks Investment Research raised Strongbridge Biopharma from a sell rating to a hold rating and set a $7.25 target price on the stock in a report on Wednesday, October 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Strongbridge Biopharma has a consensus rating of Hold and a consensus price target of $12.81.
Shares of Strongbridge Biopharma (NASDAQ SBBP) traded down $0.10 during midday trading on Friday, reaching $6.80. The company’s stock had a trading volume of 215,128 shares, compared to its average volume of 384,825. The company has a debt-to-equity ratio of -1.89, a quick ratio of 4.61 and a current ratio of 4.70. Strongbridge Biopharma has a one year low of $2.10 and a one year high of $9.02. The stock has a market capitalization of $277.09, a PE ratio of -2.00 and a beta of 1.98.
Hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers acquired a new position in Strongbridge Biopharma during the second quarter worth $154,000. California State Teachers Retirement System acquired a new position in Strongbridge Biopharma during the second quarter worth $277,000. Teachers Advisors LLC acquired a new position in Strongbridge Biopharma during the second quarter worth $297,000. Bank of New York Mellon Corp acquired a new position in Strongbridge Biopharma during the second quarter worth $331,000. Finally, Schwab Charles Investment Management Inc. acquired a new position in Strongbridge Biopharma during the second quarter worth $332,000. 57.00% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “BidaskClub Downgrades Strongbridge Biopharma (SBBP) to Hold” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.com-unik.info/2018/02/03/bidaskclub-downgrades-strongbridge-biopharma-sbbp-to-hold.html.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.